Jack Nielsen - 08 Jun 2023 Form 4 Insider Report for IO Biotech, Inc. (IOBT)

Reporting relationship: Director
Issuer ticker: IOBT
Reported as of: 08 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Jun 2023, 19:54:40 UTC
Prior SEC filing: 26 May 2023
Next SEC filing: 10 Jan 2024
Source filing: View source filing
Reporting owner signature: /s/ Brian Burkavage, Attorney-in-Fact for Jack B. Nielsen

Key filing fact

Jack Nielsen filed Form 4 for IO Biotech, Inc. (IOBT) on 13 Jun 2023.

Key facts

This page summarizes Jack Nielsen's Form 4 filing for IO Biotech, Inc. (IOBT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 13 Jun 2023, 19:54.

Change

Previous filing in this sequence was filed on 26 May 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IOBT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +41,533
Change %
Price: $0.000000
Shares after: 41,533
Date: 08 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 41,533
Exercise price: $2.08
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

These options vest on June 8, 2024, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control.